Novartis Reports Tumor Cases Linked to Gene Therapy
Morningstar ·
Novartis said it received nine reports of tumors in patients treated with its gene therapy Zolgensma since the drug was approved in 2019, including two with evidence linking them to the medicine.
By Adria Calatayud
Novartis said it received nine reports of tumors in patients treated with its gene therapy Zolgensma since the drug was approved in 2019, including two with evidence linking them to the medicine.
The Swiss drugmaker said both patients underwent treatment and continue to be monitored.
Read the full story at Morningstar · All coverage of this story